Neos Therapeutics (NASDAQ:NEOS) issued its quarterly earnings data on Friday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.03), MarketWatch Earnings reports. The firm had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $14.80 million. Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%.

NASDAQ:NEOS traded up $0.01 during mid-day trading on Friday, hitting $2.59. 651,079 shares of the stock traded hands, compared to its average volume of 621,268. The stock has a market cap of $83.38 million, a P/E ratio of -0.97 and a beta of 0.44. Neos Therapeutics has a 12-month low of $2.27 and a 12-month high of $11.69.

Several equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price objective on shares of Neos Therapeutics in a research note on Friday. Wells Fargo & Co reduced their price objective on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, August 9th. Zacks Investment Research cut shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Finally, ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Neos Therapeutics presently has an average rating of “Hold” and an average price target of $15.50.

In other news, Director Alan L. Heller acquired 43,478 shares of Neos Therapeutics stock in a transaction that occurred on Thursday, November 8th. The stock was bought at an average price of $2.30 per share, with a total value of $99,999.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.40% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/11/10/neos-therapeutics-neos-announces-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: What is dollar cost averaging (DCA)?

Earnings History for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.